MedTrace Logo

Gilead Sciences to Acquire Arcellx for $7.8 Billion in Cancer Immunotherapy Deal

en
English 简体中文 日本語 Deutsch Español Français Português 한국어

Gilead Sciences has agreed to buy immunotherapy cancer biotech Arcellx in a deal worth $7.8 billion, deepening its bet on cancer immunotherapy and its existing partnership with the company.

Gilead Sciences has agreed to buy immunotherapy cancer biotech Arcellx in a deal worth $7.8 billion, the companies announced Monday. The transaction deepens Gilead's bet on cancer immunotherapy and its existing Arcellx partnership.

Gilead Sciences is buying CAR-T therapy partner Arcellx for $7.8 billion. The acquisition expands Gilead's oncology portfolio through its partnership with the immunotherapy biotech company.

Arcellx trades on the Nasdaq under the ticker ACLX, while Gilead Sciences trades under GILD. The deal represents one of several major pharmaceutical transactions announced in recent weeks across the industry.

Related Entities

Companies
Mechanisms

Related Articles

Gilead to Acquire Cancer Therapy Developer Arcellx for Up to $7.8 Billion

Gilead Sciences to Acquire Arcellx for $7.8 Billion to Gain Full Control of Anito-cel

Eli Lilly Launches Zepbound KwikPen, Enters Opioid Treatment; Gilead Acquires Arcellx for $7.8B

Eli Lilly Expands Drug Pipeline with $2.4 Billion Orna Therapeutics Acquisition

Eli Lilly Acquires Orna Therapeutics for $2.4 Billion to Advance Circular RNA Platform

References

  1. Rx Rundown: Gilead Sciences , Viatris, Generate Biomedicines and more - MM+M · mmm-online.com
  2. Gilead to acquire Arcellx in $7.8B oncology biotech deal - Axios · amp.axios.com
  3. Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6 - BioPharma Dive · biopharmadive.com
Back to News